Stable Incidence and Increasing Prevalence of Primary Hyperparathyroidism in a Population-based Study in Scotland
Overview
Affiliations
Context: Previous studies, including our own, have demonstrated a highly variable incidence of primary hyperparathyroidism (PHPT) from year to year.
Objective: We planned to provide a current estimate of the incidence and prevalence of PHPT in a community-based study.
Methods: A population-based retrospective follow-up study was conducted in Tayside (Scotland) from 2007 to 2018. Record-linkage technology (demography, biochemistry, prescribing, hospital admissions, radiology, and mortality data) was used to identify all patients. Cases of PHPT were defined as those with at least 2 raised serum corrected calcium concentration CCA (> 2.55 mmol/L) and/or hospital admissions with PHPT diagnoses and/or surgery records with parathyroidectomy during the follow-up period. The number of prevalent and incident cases of PHPT per calendar year by age and sex were estimated.
Results: A total of 2118 people (72.3% female, mean age 65 years) were identified with an incident case of PHPT. The overall prevalence of PHPT over the 12 years of the study was 0.84% (95% CI, 0.68%-1.02%), steadily increasing from 0.71% in 2007 to 1.02% in 2018. From 2008, the incidence of PHPT was relatively stable from 4 to 6 cases per 10 000 person-years, declining from 11.5 per 10 000 person-years in 2007. The incidence varied from 0.59 per 10 000 person-years (95% CI, 0.40%-0.77%) for those aged 20 to 29 years, to 12.4 per 10 000 person-years (95% CI, 11.2%-13.3%) in those aged 70 to 79 years. Incidence of PHPT was 2.5 times higher in women than in men.
Conclusion: This study is the first showing a relatively steady annual incidence of PHPT at 4 to 6 per 10 000 person-years. This population-based study reports a PHPT prevalence of 0.84%.
Song K, Vijjhalwar R, Aye M, Comninos A, Schini M, Abbas A J Endocr Soc. 2025; 9(2):bvae225.
PMID: 39876875 PMC: 11772554. DOI: 10.1210/jendso/bvae225.
Paz-Ibarra J, Concepcion-Zavaleta M, Coronado-Arroyo J, Quiroz-Aldave J, Pino-Godoy P, Diaz-Lazo H Obstet Med. 2024; :1753495X241249201.
PMID: 39553190 PMC: 11563524. DOI: 10.1177/1753495X241249201.
Outcome of Primary Hyperparathyroidism: Retrospective Tertiary Center Experience From Basrah, Iraq.
Abdul Khaleq S, Nwayyir H, Mansour A Cureus. 2024; 16(7):e65901.
PMID: 39219874 PMC: 11364918. DOI: 10.7759/cureus.65901.
Kim K, Baek S, Yu M, Shin S, Cho S, Rhee Y JBMR Plus. 2024; 8(7):ziae065.
PMID: 38868595 PMC: 11166891. DOI: 10.1093/jbmrpl/ziae065.
Herreros-Carretero A, Berlanga-Macias C, Martinez-Vizcaino V, Torres-Costoso A, Pascual-Morena C, Hernandez-Castillejo L Transpl Int. 2024; 37():12312.
PMID: 38720821 PMC: 11076774. DOI: 10.3389/ti.2024.12312.